IPCI.TO - IntelliPharmaCeutics International Inc.

Toronto - Toronto Delayed Price. Currency in CAD
0.4200
-0.0400 (-8.70%)
At close: 11:38AM EST
Stock chart is not supported by your current browser
Previous Close0.4600
Open0.4600
Bid0.42 x 0
Ask0.51 x 0
Day's Range0.4200 - 0.4600
52 Week Range0.2700 - 9.0000
Volume7,650
Avg. Volume25,585
Market Cap4.041M
Beta (3Y Monthly)4.68
PE Ratio (TTM)N/A
EPS (TTM)-3.26
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.00
  • ACCESSWIRE22 days ago

    Intellipharmaceutics Receives Extension from Nasdaq Hearings Panel

    TORONTO, ONTARIO / ACCESSWIRE / January 28, 2019 / Intellipharmaceutics International Inc. (NASDAQ: IPCI) and (TSX: IPCI) (''Intellipharmaceutics'' or the ''Company''), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has received notice from the Nasdaq Hearings Panel (the ''Panel'') extending the continued listing of the Company's common shares until March 7, 2019, subject to certain conditions, while the Company works to regain compliance with Nasdaq's requirements. At a hearing held on January 10, 2019, the Company presented its plan to regain and maintain compliance with Nasdaq's continued listing requirements.

  • ACCESSWIRE29 days ago

    Today's Research Reports on ESSA Pharma, OrganiGram, IntelliPharmaCeutics International and Centric Health

    NEW YORK, NY / ACCESSWIRE / January 22, 2019 / The Market Wealth Report strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • ACCESSWIRElast month

    Intellipharmaceutics Announces Research and Development Program for a Pipeline of Pharmaceutical Cannabidiol Based Products

    TORONTO, ON / ACCESSWIRE / January 7, 2019 / Intellipharmaceutics International Inc. (NASDAQ: IPCI) and (TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has commenced a research and development program of pharmaceutical cannabidiol ("CBD") based products. The Company believes that its current technology platforms could find use in cannabidiol therapeutics.

  • ACCESSWIRE2 months ago

    Today's Research Reports on IntelliPharmaCeutics International, Centric Health, Knight Therapeutics and Oncolytics Biotech

    NEW YORK, NY / ACCESSWIRE / December 11, 2018 / The Market Edge strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us ...

  • ACCESSWIRE3 months ago

    NASDAQ Schedules Hearing to Consider Intellipharmaceutics’ (TM) Continued Listing

    TORONTO, ON / ACCESSWIRE / December 5, 2018 / Intellipharmaceutics International Inc. (NASDAQ and TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has received written notification (the ''Notification'')from The Nasdaq Stock Market LLC ('NASDAQ'') notifying the Company that a hearing with a Nasdaq Hearings Panel (the ''Panel'')has been scheduled for January 10, 2019. As previously reported, the minimum bid price per share for the Company's common shares was below $1.00 for a period of 30 consecutive business days and, as a result, the Company is currently not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2).

  • Benzinga3 months ago

    The Daily Biotech Pulse: IntelliPharmaCeutics Generic Antidepressant Gets FDA Nod, GW Pharma Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. None of the biotech stocks hit 52-week highs Tuesday. Down In The Dumps (Biotech stocks hitting 52-week lows on Nov. 27) ...

  • ACCESSWIRE3 months ago

    Intellipharmaceutics Announces FDA Final Approval of Generic Effexor® XR

    TORONTO, ON / ACCESSWIRE / November 27, 2018 / Intellipharmaceutics International Inc. (NASDAQ and TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has received final approval from the U.S. Food and Drug Administration ("FDA") for the Company's abbreviated new drug application ("ANDA") for venlafaxine hydrochloride extended-release capsules in the 37.5, 75, and 150 mg strengths. The approved product is a generic equivalent of the branded product Effexor® XR sold in the U.S. by Wyeth Pharmaceuticals, LLC.

  • ACCESSWIRE3 months ago

    Intellipharmaceutics Submits Investigational New Drug Application to the U.S. FDA for IPCI006 (oxycodone hydrochloride immediate release) Tablets Incorporating its Abuse Deterrent and Overdose Resistant Technology

    TORONTO, ON / ACCESSWIRE / November 27, 2018 / Intellipharmaceutics International Inc. (NASDAQ and TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has submitted an investigational new drug ("IND") application to the U.S. Food and Drug Administration ("FDA") for its oxycodone hydrochloride immediate release ("IPCI006") tablets in the 5 mg, 10 mg, 15 mg, 20 mg and 30 mg strengths. Oxycodone hydrochloride is indicated for the management of moderate to severe pain where the use of an opioid analgesic is appropriate. This novel drug formulation incorporates the Company's Paradoxical OverDose Resistance Activating System ("PODRAS™") delivery technology and its novel Point Of Divergence Drug Delivery System ("nPODDDS™") technology.

  • ACCESSWIRE3 months ago

    Intellipharmaceutics Announces Receipt of Nasdaq Notice

    TORONTO, ON / ACCESSWIRE / November 26, 2018 / Intellipharmaceutics International Inc. (Nasdaq and TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has received written notification (the "Notification Letter") from The Nasdaq Stock Market LLC notifying the Company that the minimum bid price per share for its common shares was below $1.00 for a period of 30 consecutive business days and that, as a result, the Company is currently not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). The Company is not eligible for a grace period to regain compliance.

  • ACCESSWIRE3 months ago

    Intellipharmaceutics Reports Exclusive Supply Agreement for its Abuse-Deterrent Oxycodone ER Product Candidate and Four Generic Drug Products in the Philippines

    TSX: IPCI) (''Intellipharmaceutics'' or the ''Company''), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced it has entered into an exclusive licensing and distribution agreement for its abuse resistant Oxycodone ER product candidate and four generic drug products with a pharmaceutical distributor in the Philippines. ''Our supply agreement in the Philippines is another step forward in Intellipharmaceutics' goal to impact the global opioid market,'' commented Dr. Isa Odidi, CEO of Intellipharmaceutics.

  • ACCESSWIRE3 months ago

    Intellipharmaceutics Reports Exclusive Distribution Agreements in Malaysia and Vietnam

    TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced it has entered into two exclusive licensing and distribution agreements with pharmaceutical distributors in Malaysia and Vietnam. "We are extremely pleased to announce our entry into agreements for non-US generics in these markets," commented Dr. Isa Odidi, CEO of the Company. "Intellipharmaceutics has a strong portfolio of U.S. FDA approved generics and is committed to monetizing them by aggressively pursuing global partnerships.

  • ACCESSWIRE3 months ago

    Today's Research Reports on ProMIS Neurosciences, IntelliPharmaCeutics International, Centric Health and Theratechnologies

    NEW YORK, NY / ACCESSWIRE / November 12, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • ACCESSWIRE3 months ago

    Intellipharmaceutics Announces Resignation of Chief Financial Officer

    TORONTO, ON / ACCESSWIRE / November 5, 2018 / Intellipharmaceutics International Inc. (NASDAQ and TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced the resignation of Andrew Patient, Chief Financial Officer, effective November 30, 2018 to pursue another opportunity. Mr. Patient has agreed to continue to offer his services to the Company through December 31, 2018 and is willing to continue thereafter on a consulting basis at the Company's discretion. Dr. Isa Odidi, Chairman, Chief Executive Officer and Co-Chief Scientist of the Company, commented "On behalf of the management team and the Board of Directors, I would like to thank Andrew for his contributions to Intellipharmaceutics, and to wish him every future success.

  • ACCESSWIRE4 months ago

    Intellipharmaceutics Regains Compliance with Nasdaq Minimum Shareholders' Equity Listing Requirements

    TORONTO, ON / ACCESSWIRE / October 26, 2018 / Intellipharmaceutics International Inc. (NASDAQ and TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has received a letter from the Hearings Advisor from the Nasdaq Office of General Counsel notifying the Company that it had regained compliance with Nasdaq's stockholders' equity requirement. The letter also informed the Company that the Company will remain subject to a "Panel Monitor" under Nasdaq Listing Rule 5815(d)(4)(A) until October 22, 2019.

  • ACCESSWIRE4 months ago

    Intellipharmaceutics Announces Closing of US $14.3 Million Underwritten Public Offering

    TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced the closing of its previously announced underwritten public offering in the United States, resulting in the sale of 2,775,231 common shares, pre-funded warrants exercisable for 16,563,335 common shares, at an exercise price of US$0.01 per share (the "Pre-Funded Warrants"), and warrants exercisable for 20,000,000 common shares, at an exercise price of US$0.75 per share (the "Firm Warrants").

  • ACCESSWIRE4 months ago

    Intellipharmaceutics Announces Third Quarter 2018 Results

    TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three and nine months ended August 31, 2018. "We made great progress with respect to our development programs in the third quarter, despite challenging financial circumstances," said Dr. Isa Odidi, CEO of Intellipharmaceutics. In October 2018, we entered into an Underwriting Agreement (the "Underwriting Agreement") with H.C. Wainwright & Co., LLC ("H.C. Wainwright"), pursuant to which we agreed to issue and sell, in an underwritten public offering (the "October 2018 Offering"), 827,970 common shares and an aggregate of 16,563,335 pre-funded warrants ("Pre-Funded Warrants") exercisable into an aggregate of 16,563,335 common shares (the "Warrant Shares") together with common share purchase warrants to purchase up to an aggregate of 17,391,305 common shares ("Firm Warrants").

  • ACCESSWIRE4 months ago

    Today's Research Reports on Theratechnologies, IntelliPharmaCeutics International, Centric Health and ProMIS Neurosciences

    NEW YORK, NY / ACCESSWIRE / October 15, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • Benzinga4 months ago

    Don't Fixate On Market Woes, Just Make Your Trades

    Beyond my recent losses, October has actually been a strong month for me, although some in the chat are wondering how the recent market-wide selloff is affecting day traders. It was a fairly typical day for me, I was up, then down, then up again. Two of the top stocks to appear on my premarket scanner on Thursday, Spherix Inc. (NASDAQ: SPEX) and Compugen Ltd. (NASDAQ: CGEN), both collapsed on the opening bell.

  • ACCESSWIRE4 months ago

    Intellipharmaceutics Announces Pricing of $13 Million Upsized Underwritten Public Offering

    TSX: IPCI) (''Intellipharmaceutics'' or the ''Company''), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced the pricing of an underwritten public offering of an aggregate of 17,391,305 units. Each unit is comprised of one common share (or common share equivalent) and one warrant to purchase one common share. The units are being offered at a public offering price of $0.75 per unit.

  • ACCESSWIRE4 months ago

    Intellipharmaceutics Announces Completion of the Clinical Component of Category 2 and 3 Human Abuse Liability Studies for Oxycodone ER

    TORONTO, ON / ACCESSWIRE / October 10, 2018 / Intellipharmaceutics International Inc. (NASDAQ: IPCI; TSX : IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company ...

  • ACCESSWIRE5 months ago

    Intellipharmaceutics Regains Compliance with NASDAQ Minimum Bid Price Requirement; Also Receives Requested Extension from NASDAQ Panel

    TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has received a letter from Nasdaq Listing Qualifications notifying the Company that it had regained compliance with Nasdaq's minimum bid price requirement. The letter noted that as of September 28, 2018, the Company evidenced a closing bid price of its common shares in excess of the $1.00 minimum requirement for at least ten consecutive business days.

  • ACCESSWIRE5 months ago

    Today's Research Reports on IntelliPharmaCeutics International, Centric Health, ProMIS Neurosciences and Theratechnologies

    NEW YORK, NY / ACCESSWIRE / September 14, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • ACCESSWIRE5 months ago

    Intellipharmaceutics Announces One-for-10 Reverse Stock Split

    TORONTO, ONTARIO / ACCESSWIRE / September 13, 2018 / Intellipharmaceutics International Inc. (NASDAQ and TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid-dosage drugs, announced today that it implemented a one-for-ten share consolidation (the "reverse split"). At a special meeting of the Company's shareholders held on August 15, 2018, the Company's shareholders granted the Company's Board of Directors discretionary authority to implement a consolidation of the issued and outstanding common shares of the Company on the basis of a consolidation ratio within a range from five (5) pre-consolidation common shares for one (1) post-consolidation common share to fifteen (15) pre-consolidation common shares for one (1) post-consolidation common share.